Company Overview

McKesson Corporation is a diversified global leader in healthcare services, dedicated to advancing health outcomes for patients everywhere. As an American publicly traded company, McKesson plays a crucial role in distributing pharmaceuticals and providing essential health information technology, medical supplies, and health management tools. The company is a vital link in the healthcare supply chain, delivering approximately a third of all pharmaceutical products used or consumed in North America. McKesson employs over 80,000 dedicated professionals.

With significant revenue, reported at $308.9 billion for fiscal year 2024, McKesson ranks as the ninth-largest company by revenue in the United States and is recognized as the nation's largest health care company. The company is headquartered in Irving, Texas. It is a prominent component of the S&P 500 index and is listed on the New York Stock Exchange under the ticker symbol "MCK". Founded in 1833, McKesson has a long-standing history in the healthcare industry.

Business Segments and Operations

McKesson operates through four distinct business segments, each contributing to its broad healthcare ecosystem:

U.S. Pharmaceutical Segment

This is McKesson's largest segment, generating $278.74 billion in revenue, which constitutes 90.22% of its total revenue. The U.S. Pharmaceutical segment is responsible for distributing a wide array of products including branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, alongside other healthcare-related products.

Prescription Technology Solutions (RxTS)

Generating $4.77 billion in revenue (1.54% of total revenue), the RxTS segment is designed to serve biopharma and life sciences partners. It focuses on addressing patient challenges by connecting various stakeholders across the healthcare landscape, including patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS delivers solutions aimed at improving medication access and affordability, providing prescription decision support, enhancing prescription price transparency, offering benefit insights, and supporting dispensing and third-party logistics, including wholesale distribution support services and electronic prior authorization.

Medical-Surgical Solutions

This segment generated $11.31 billion in revenue, accounting for 3.66% of total revenue. The Medical-Surgical Solutions segment provides essential medical-surgical supply distribution, logistics, and biomedical maintenance services. Its customer base includes a variety of healthcare providers such as physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies.

International Segment

The International segment generated $14.13 billion in revenue, representing 4.57% of total revenue. This segment offers distribution and services to wholesale, institutional, and retail customers primarily located in Europe and Canada.

Financial Performance

Latest Financial Results (Q2 FY25 - Ended September 30, 2024)

- Consolidated Revenues: $93.7 billion, marking a 21% increase year-over-year.

- Adjusted Earnings Per Diluted Share: $7.07, an increase of 13% compared to the previous year ($6.23). This growth was primarily driven by robust performance in the U.S. Pharmaceutical segment and a reduced share count.

Fiscal Year 2024 Results (Ended March 31, 2024)

- Revenues: $278.7 billion, reflecting a 16% increase. This growth was fueled by higher prescription volumes, particularly from specialty products, retail national account customers, and GLP-1 medications.

- Segment Operating Profit: $2.8 billion.

- Full Year Adjusted Earnings Per Diluted Share: $27.44, an increase of 6% from $25.94 in the prior year. This was led by growth in the U.S. Pharmaceutical and Prescription Technology Solutions segments, coupled with a lower share count, though partially offset by higher corporate expenses.

Cash Flow and Capital Allocation

- Cash Returned to Shareholders (Full Year FY24): $3.3 billion, comprising $3.0 billion in common stock repurchases and $314 million in dividend payments.

- Cash from Operations: $4.3 billion.

- Capital Expenditures: $687 million.

- Free Cash Flow: $3.6 billion.

Market Position

McKesson Corporation is one of the three leading pharmaceutical wholesalers in the United States. Along with Cencora (formerly AmerisourceBergen) and Cardinal Health, these three companies collectively account for over 90% of the U.S. pharmaceutical wholesale market. McKesson's core business involves sourcing and distributing branded, generic, and specialty pharmaceutical products to a wide range of customers, including retail pharmacies (chains, independents, and mail order), hospital networks, and other healthcare providers.

Recent Developments and Strategic Initiatives

- Acquisition Agreement: McKesson announced an agreement to acquire a controlling interest in Florida Cancer Specialists & Research Institute LLC's Core Ventures, expanding its presence in specialized oncology services.

- Divestiture: McKesson announced an agreement to sell its Canada-based retail businesses, Rexall and Well.ca.

- Transaction Closing: On December 30, 2024, McKesson successfully closed the transaction for the sale of its Canada-based Rexall and Well.ca retail businesses.

Technology and Innovation

McKesson is a significant provider of critical infrastructure for the healthcare industry. The company has a history of early adoption of innovative technologies, including barcode scanning for distribution, pharmacy robotics, and RFID tags. Their extensive customer network in the United States includes:

- 50% of all health systems.

- 20% of all physician practices.

- 25% of home care agencies.

- 77% of health systems with more than 200 beds.

Company Recognition

McKesson has been consistently recognized for its commitment to diversity, inclusion, and employee well-being:

- Newsweek: Recognized as one of America's Greatest Workplaces for Women in 2024.

- DiversityComm Media: Named a 2024 Best of the Best Top Women Employer.

- Disability Inclusion: Honored as a "Best Place to Work for Disability Inclusion" for the ninth consecutive year. McKesson achieved a top-ranking score of 100 on the 2024 Disability Equality Index® (DEI), a joint initiative by the American Association of People with Disabilities and Disability:IN.

McKesson Corporation stands as a cornerstone of the American healthcare distribution system, with its comprehensive network enabling critical pharmaceutical and medical supply distribution across North America. The company's strong financial performance, strategic investments in specialized areas like oncology services, and dedication to leveraging healthcare technology innovation position it as an indispensable player in the dynamic and evolving global healthcare landscape.